HNN3.0

Project cooperationUpdated on 13 January 2026

Evidence that Drives Decisions: Health Technology Assessment (HTA) for Horizon Europe

Project Manager at Consorzio Italbiotec

Milan, Italy

About

Consorzio Italbiotec provides expert support in Health Technology Assessment (HTA) within Health projects, helping consortia generate robust evidence to support clinical relevance, economic value and societal impact of health innovations. Our HTA services are designed to strengthen both project implementation and impact sections, through early and parallel HTA approaches that guide technology development. Activities include the assessment of clinical effectiveness, safety and comparative value, health economic analyses and cost-effectiveness considerations, as well as the evaluation of organisational, ethical and social implications of health technologies. By integrating HTA methodologies from the early stages of R&I projects, Consorzio Italbiotec supports the alignment of innovations with healthcare system needs, payer expectations and regulatory frameworks, enabling evidence-based decision-making and facilitating future adoption, reimbursement and scale-up. All HTA activities are aligned with EU HTA principles, Horizon Europe impact requirements and patient-centred innovation approaches, ensuring relevance for decision-makers, healthcare providers and policy stakeholders.

📩 We are interested in collaborating with companies and research organisations seeking HTA expertise to strengthen the credibility, uptake potential and long-term impact of their health projects.

Topic

  • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

Type

  • Consortium/Coordinator seeks Partners
  • Partner seeks Consortium/Coordinator

Organisation

Consorzio Italbiotec

Other

Milan, Italy

Similar opportunities

  • Project cooperation

    Evidence that Drives Decisions: Health Technology Assessment (HTA) for Horizon Europe

    • Consortium/Coordinator seeks Partners
    • Partner seeks Consortium/Coordinator

    Emanuele Melfitani

    Life Science R&D Project Manager at Consorzio Italbiotec

    Milan, Italy

  • Project cooperation

    Health economics & HTA expertise for Horizon Europe Cluster Health consortia, with a focus on rare and small-population settings.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Persefoni Kritikou

    Founder & Health Economist at Rare Disease Consulting

    Athens, Greece

  • Project cooperation

    Making Innovation Matter: Dissemination & Exploitation in EU projects

    • Consortium/Coordinator seeks Partners
    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Francesco Tesoro

    Project Manager at Consorzio Italbiotec

    Milan, Italy